The concept of treating to a target of remission is gaining ground in systemic lupus erythematosus. New research suggests that achievement of this treatment goal is rare, but are the definitions of remission used in these studies fit for purpose?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
Arthritis Research & Therapy Open Access 20 March 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73, 958–967 (2014).
Franklyn, K., Hoi, A., Nikpour, M. & Morand, E. F. The need to define treatment goals for systemic lupus erythematosus. Nat. Rev. Rheumatol. 10, 567–571 (2014).
Wilhelm, T. R., Magder, L. S. & Petri, M. Remission in systemic lupus erythematosus: durable remission is rare. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-209489 (2016).
Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3–15 (2016).
Apostolopoulos, D. & Morand, E. F. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford) (in press) (2016).
Franklyn, K. et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann. Rheum. Dis. 75, 1615–1621 (2016).
Zen, M. et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann. Rheum. Dis. 74, 2117–2122 (2015).
Petri, M., Purvey, S., Fang, H. & Magder, L. S. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 64, 4021–4028 (2012).
Furie, R. A. et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61, 1143–1151 (2009).
Jolly, M. et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann. Rheum. Dis. 69, 29–33 (2009).
Acknowledgements
E.F.M. is a contributor to the Definitions of Remission in SLE (DORIS) working group and a member of the Asia-Pacific Lupus Collaboration (APLC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.F.M. declares that he has received grants or research support from AstraZeneca, Janssen, GSK and UCB; received speaker's honoraria from UCB; and acted as a consultant for AstraZeneca and Pfizer.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Morand, E. Remission in SLE — are we there yet?. Nat Rev Rheumatol 12, 696–698 (2016). https://doi.org/10.1038/nrrheum.2016.174
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.174
This article is cited by
-
Impact of follow-up visits on disease outcome in Chinese systemic lupus erythematosus
Clinical Rheumatology (2018)
-
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
Arthritis Research & Therapy (2017)